skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 121  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: subject: General & Internal Medicine remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Material Type:
Article
Add to My Research

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

The New England journal of medicine, 2017-05, Vol.376 (18), p.1713-1722 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615664 ;PMID: 28304224

Full text available

2
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Material Type:
Article
Add to My Research

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

The Lancet (British edition), 2017-04, Vol.389 (10077), p.1399-1409 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 8, 2017 ;2017. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30069-7 ;PMID: 28237263

Full text available

3
Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
Material Type:
Article
Add to My Research

Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation

The New England journal of medicine, 2014-12, Vol.371 (25), p.2363-2374 [Peer Reviewed Journal]

Copyright © 2014 Massachusetts Medical Society. All rights reserved. ;Copyright © 2014 Massachusetts Medical Society. 2014 ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1408028 ;PMID: 25470569

Full text available

4
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Material Type:
Article
Add to My Research

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

The New England journal of medicine, 2011-03, Vol.364 (10), p.907-917 [Peer Reviewed Journal]

Copyright © 2011 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1007994 ;PMID: 21388309 ;CODEN: NEJMAG

Full text available

5
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Material Type:
Article
Add to My Research

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The New England journal of medicine, 2010-09, Vol.363 (10), p.905-917 [Peer Reviewed Journal]

Copyright © 2010 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1003114 ;PMID: 20818901 ;CODEN: NEJMAG

Full text available

6
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
Material Type:
Article
Add to My Research

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

The New England journal of medicine, 2010-04, Vol.362 (16), p.1477-1490 [Peer Reviewed Journal]

Copyright © 2010 Massachusetts Medical Society. All rights reserved. ;2010 Massachusetts Medical Society ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1001121 ;PMID: 20228403 ;CODEN: NEJMAG

Full text available

7
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
Material Type:
Article
Add to My Research

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

The New England journal of medicine, 2010-04, Vol.362 (16), p.1463-1476 [Peer Reviewed Journal]

Copyright © 2010 Massachusetts Medical Society. All rights reserved. ;2010 Massachusetts Medical Society ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1001122 ;PMID: 20228402 ;CODEN: NEJMAG

Full text available

8
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Material Type:
Article
Add to My Research

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

The Lancet (British edition), 2005-10, Vol.366 (9493), p.1279-1289 [Peer Reviewed Journal]

2005 Elsevier Ltd ;Copyright Lancet Ltd. Oct 8-Oct 14, 2005 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)67528-9 ;PMID: 16214598 ;CODEN: LANCAO

Full text available

9
Physical activity enhances the improvement of body mass index and metabolism by inulin: a multicenter randomized placebo-controlled trial performed in obese individuals
Material Type:
Article
Add to My Research

Physical activity enhances the improvement of body mass index and metabolism by inulin: a multicenter randomized placebo-controlled trial performed in obese individuals

BMC medicine, 2022-03, Vol.20 (1), p.110-110, Article 110 [Peer Reviewed Journal]

2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;The Author(s) 2022 ;ISSN: 1741-7015 ;EISSN: 1741-7015 ;DOI: 10.1186/s12916-022-02299-z ;PMID: 35351144

Full text available

10
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Material Type:
Article
Add to My Research

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

The Lancet (British edition), 2006-11, Vol.368 (9548), p.1660-1672 [Peer Reviewed Journal]

2006 Elsevier Ltd ;Copyright Lancet Ltd. Nov 11-Nov 17, 2006 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(06)69571-8 ;PMID: 17098084 ;CODEN: LANCAO

Full text available

11
Safety, efficacy and clinical generalization of the STAR protocol: a retrospective analysis
Material Type:
Article
Add to My Research

Safety, efficacy and clinical generalization of the STAR protocol: a retrospective analysis

Annals of intensive care, 2016-03, Vol.6 (1), p.24-24, Article 24 [Peer Reviewed Journal]

Stewart et al. 2016 ;Annals of Intensive Care is a copyright of Springer, 2016. ;ISSN: 2110-5820 ;EISSN: 2110-5820 ;DOI: 10.1186/s13613-016-0125-9 ;PMID: 27025951

Full text available

12
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Material Type:
Article
Add to My Research

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

The Lancet (British edition), 2005-04, Vol.365 (9468), p.1389-1397 [Peer Reviewed Journal]

2005 Elsevier Ltd ;Copyright Lancet Ltd. Apr 16-Apr 22, 2005 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)66374-X ;PMID: 15836887 ;CODEN: LANCAO

Full text available

13
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
Material Type:
Article
Add to My Research

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

The Lancet (British edition), 2010, Vol.376 (9740), p.517-523 [Peer Reviewed Journal]

Elsevier Ltd ;2010 Elsevier Ltd ;2015 INIST-CNRS ;Copyright 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 14-Aug 20, 2010 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(10)60935-X ;PMID: 20709233 ;CODEN: LANCAO

Full text available

14
Insulin sensitivity in critically ill patients: are women more insulin resistant?
Material Type:
Article
Add to My Research

Insulin sensitivity in critically ill patients: are women more insulin resistant?

Annals of intensive care, 2021-01, Vol.11 (1), p.12-12, Article 12 [Peer Reviewed Journal]

The Author(s) 2021 ;COPYRIGHT 2021 Springer ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2110-5820 ;EISSN: 2110-5820 ;DOI: 10.1186/s13613-021-00807-7 ;PMID: 33475909

Full text available

15
Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess
Material Type:
Article
Add to My Research

Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess

Journal of clinical medicine, 2022-04, Vol.11 (8), p.2168 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm11082168 ;PMID: 35456261

Full text available

16
The Role of MCM9 in the Etiology of Sertoli Cell-Only Syndrome and Premature Ovarian Insufficiency
Material Type:
Article
Add to My Research

The Role of MCM9 in the Etiology of Sertoli Cell-Only Syndrome and Premature Ovarian Insufficiency

Journal of clinical medicine, 2023-01, Vol.12 (3), p.990 [Peer Reviewed Journal]

2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm12030990 ;PMID: 36769638

Full text available

17
Inflammatory markers and cardiometabolic diseases
Material Type:
Article
Add to My Research

Inflammatory markers and cardiometabolic diseases

Acta clinica belgica (English ed. Online), 2015-06, Vol.70 (3), p.193-199 [Peer Reviewed Journal]

Acta Clinica Belgica 2015 2015 ;Copyright Maney Publishing 2015 ;ISSN: 1784-3286 ;ISSN: 2295-3337 ;EISSN: 2295-3337 ;DOI: 10.1179/2295333715Y.0000000004 ;PMID: 26103538

Full text available

18
Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview
Material Type:
Article
Add to My Research

Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview

Journal of clinical medicine, 2020-06, Vol.9 (6), p.2003 [Peer Reviewed Journal]

2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm9062003 ;PMID: 32604740

Full text available

19
Gliptin versus a sulphonylurea as add-on to metformin
Material Type:
Article
Add to My Research

Gliptin versus a sulphonylurea as add-on to metformin

The Lancet (British edition), 2012-08, Vol.380 (9840), p.450-452 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;Copyright Elsevier Limited Aug 4-Aug 10, 2012 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60859-9 ;PMID: 22748818 ;CODEN: LANCAO

Full text available

20
Which incretin-based therapy for type 2 diabetes?
Material Type:
Article
Add to My Research

Which incretin-based therapy for type 2 diabetes?

The Lancet (British edition), 2014-10, Vol.384 (9951), p.1325-1327 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;Copyright Elsevier Limited Oct 11, 2014 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61097-7 ;PMID: 25018117 ;CODEN: LANCAO

Full text available

Results 1 - 20 of 121  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1999  (6)
  2. 1999 To 2004  (39)
  3. 2005 To 2009  (53)
  4. 2010 To 2016  (15)
  5. After 2016  (9)
  6. More options open sub menu

Resource Type 

  1. Web Resources  (77)
  2. Articles  (44)
  3. More options open sub menu

Language 

  1. English  (118)
  2. Japanese  (12)
  3. French  (3)
  4. Portuguese  (1)
  5. More options open sub menu

Searching Remote Databases, Please Wait